Polymorphism in the CYP2R1 gene

Oct 13, 2025 by sorusgentrification.com 130 views

The Influence of Polymorphism of the Cyp2R1 Receptor Gene (RS 10741657) with Vitamin D Levels

Introduction

Breast cancer is a significant global health concern, with high morbidity and mortality rates. The causes of this disease are multifactorial, and one of the factors that is still being debated is vitamin D deficiency. Vitamin D deficiency is influenced by various factors, including sun exposure, skin color, eating patterns, and genetic variations in genes that play a role in metabolism and catabolism of vitamin D. The Cyp2R1 gene, which encodes the 25-hydroxylase enzyme, is crucial in the process of vitamin D metabolism. This enzyme serves to convert vitamin D3 to 25 (OH) D in the liver. Polymorphism in the CYP2R1 gene can reduce the effectiveness of the 25-hydroxylase enzyme, resulting in a reduced amount of vitamin D3 converted to 25 (OH) D.

Vitamin D plays a vital role in maintaining bone health, immune function, and cell growth regulation. Breast cancer patients with vitamin D deficiency have been shown to have a higher risk of developing the disease. Therefore, understanding the relationship between vitamin D levels and genetic variations in the CYP2R1 gene is essential in developing effective prevention and treatment strategies for breast cancer.

Research Methods

This study employed a cross-sectional design with an analytical observation type, adopting the Consecutive Sampling technique. The purpose of this study was to analyze the relationship between the Cyp2R1 RS10741657 gene polymorphism and vitamin D levels in breast cancer patients. The sample consisted of 53 breast cancer patients who had just been diagnosed. Vitamin D levels were measured using the ELISA method, while gene polymorphism examination was carried out by the PCR-RFLP method using the MN1i restriction enzyme.

Research Results

The results showed the existence of all variants of CYP2R1 RS10741657 polymorphism, namely AA (9.43%), GA (54.71%), and GG (35.84%). The population in this study was in accordance with the Hardy-Weinberg equilibrium (p = 0.199). Vitamin D levels obtained were mostly in the Sufisiency group (45.28%), followed by insufficiency groups (35.84%), and deficiency groups (18.86%). Fisher Exact test showed that there was no significant relationship between the CYP2R1 gene polymorphism (RS10741657) and vitamin D levels in breast cancer patients (p = 0.849).

Conclusion

Based on this study, there was no relationship between the CYP2R1 RS10741657 gene polymorphism and vitamin D levels. This might be caused by a fairly good source of vitamin D in the research subject, so that the decline in the effectiveness of the 25-hydroxylase enzyme did not have a significant impact on vitamin D levels in the body. This finding gives additional insight into the importance of considering various factors that affect vitamin D levels, especially in the context of breast cancer.

Analysis

The importance of this study lies in a deeper understanding of genetic interactions and vitamin D levels, especially in the context of breast cancer. Although the results show the absence of a significant relationship, this finding provides valuable information about the factors that contribute to vitamin D levels. This also shows that even with gene polymorphism that may affect metabolism, good vitamin D intake can still support adequate vitamin D levels.

Thus, although there are genetic variations, it is essential for breast cancer patients to pay attention to their vitamin D intake through adequate sun exposure and consumption of foods that are rich in vitamin D. Further research in this field can help clarify the relationship between genetic factors, the environment, and vitamin D status in a wider population.

Implications for Future Research

This study highlights the need for further research on the relationship between genetic variations, vitamin D levels, and breast cancer. Understanding the complex interactions between these factors can help develop effective prevention and treatment strategies for breast cancer. Future studies should investigate the impact of vitamin D supplementation on breast cancer patients with CYP2R1 gene polymorphism. Additionally, research should focus on the role of other genetic variants in vitamin D metabolism and their impact on breast cancer risk.

Limitations of the Study

This study had several limitations. The sample size was relatively small, and the study was conducted in a single population. Additionally, the study only examined the relationship between CYP2R1 gene polymorphism and vitamin D levels, and did not investigate other potential factors that may influence vitamin D levels. Future studies should aim to address these limitations and provide a more comprehensive understanding of the relationship between genetic variations, vitamin D levels, and breast cancer.

Conclusion

In conclusion, this study found no significant relationship between the CYP2R1 RS10741657 gene polymorphism and vitamin D levels in breast cancer patients. However, this finding highlights the importance of considering various factors that affect vitamin D levels, especially in the context of breast cancer. Further research is needed to clarify the relationship between genetic factors, the environment, and vitamin D status in a wider population.
Frequently Asked Questions (FAQs) about the Influence of Polymorphism of the Cyp2R1 Receptor Gene (RS 10741657) with Vitamin D Levels

Q: What is the Cyp2R1 gene, and what role does it play in vitamin D metabolism?

A: The Cyp2R1 gene encodes the 25-hydroxylase enzyme, which is crucial in the process of vitamin D metabolism. This enzyme serves to convert vitamin D3 to 25 (OH) D in the liver.

Q: What is polymorphism in the CYP2R1 gene, and how does it affect vitamin D levels?

A: Polymorphism in the CYP2R1 gene can reduce the effectiveness of the 25-hydroxylase enzyme, resulting in a reduced amount of vitamin D3 converted to 25 (OH) D. This can lead to lower vitamin D levels in the body.

Q: What is the relationship between vitamin D levels and breast cancer?

A: Vitamin D plays a vital role in maintaining bone health, immune function, and cell growth regulation. Breast cancer patients with vitamin D deficiency have been shown to have a higher risk of developing the disease.

Q: What is the significance of this study in understanding the relationship between genetic variations and vitamin D levels?

A: This study highlights the importance of considering various factors that affect vitamin D levels, especially in the context of breast cancer. Understanding the complex interactions between genetic variations, vitamin D levels, and breast cancer can help develop effective prevention and treatment strategies for breast cancer.

Q: What are the implications of this study for breast cancer patients?

A: Although there are genetic variations, it is essential for breast cancer patients to pay attention to their vitamin D intake through adequate sun exposure and consumption of foods that are rich in vitamin D.

Q: What are the limitations of this study?

A: This study had several limitations, including a relatively small sample size and the study being conducted in a single population. Additionally, the study only examined the relationship between CYP2R1 gene polymorphism and vitamin D levels, and did not investigate other potential factors that may influence vitamin D levels.

Q: What are the future research directions in this field?

A: Future studies should investigate the impact of vitamin D supplementation on breast cancer patients with CYP2R1 gene polymorphism. Additionally, research should focus on the role of other genetic variants in vitamin D metabolism and their impact on breast cancer risk.

Q: How can individuals with CYP2R1 gene polymorphism maintain adequate vitamin D levels?

A: Individuals with CYP2R1 gene polymorphism can maintain adequate vitamin D levels by consuming foods rich in vitamin D, such as fatty fish, egg yolks, and fortified dairy products. They can also consider taking vitamin D supplements after consulting with their healthcare provider.

Q: What are the potential consequences of vitamin D deficiency in breast cancer patients?

A: Vitamin D deficiency has been linked to an increased risk of breast cancer, as well as other health problems, such as osteoporosis and cardiovascular disease.

Q: How can healthcare providers help breast cancer patients with CYP2R1 gene polymorphism?

A: Healthcare providers can help breast cancer patients with CYP2R1 gene polymorphism by recommending vitamin D supplements and monitoring their vitamin D levels regularly. They can also provide guidance on maintaining adequate vitamin D levels through diet and sun exposure.

Q: What are the next steps in research on the relationship between genetic variations and vitamin D levels?

A: Future research should focus on investigating the impact of vitamin D supplementation on breast cancer patients with CYP2R1 gene polymorphism. Additionally, research should explore the role of other genetic variants in vitamin D metabolism and their impact on breast cancer risk.